Literature DB >> 30672881

Amelanotic melanoma.

Hui-Zi Gong, He-Yi Zheng, Jun Li.   

Abstract

Cutaneous amelanotic melanoma (AM) is a rare amelanotic or a hypomelanotic subtype of melanoma, comprising only 0.4-27.5% of all melanoma cases. The mean age of the patients is over 50 years, and the male/female ratio varies from 0.5 to 4. Patients with red hair, type I skin, freckles, lack of nevi on the back, a sun-sensitive phenotype, or previous AM history are more likely to develop AMs. As AMs lack pigmentation, their appearances vary and can mimic many benign and malignant conditions, thus presenting a diagnostic challenge. AMs are composed of greater proportions of nodular melanoma, acral lentiginous melanoma, and desmoplastic melanoma than pigmented melanomas. They also present with thicker Breslow thickness, higher mitotic rate, more frequent ulceration, higher tumor stage, and lower survival than pigmented melanomas.

Entities:  

Mesh:

Year:  2019        PMID: 30672881     DOI: 10.1097/CMR.0000000000000571

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  12 in total

Review 1.  Primary malignant melanomas of the female lower genital tract: clinicopathological characteristics and management.

Authors:  Dongying Wang; Tianmin Xu; He Zhu; Junxue Dong; Li Fu
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

2.  Risk Factors and Predictors of Survival Among Patients with Amelanotic Melanoma Compared to Melanotic Melanoma in the National Cancer Database.

Authors:  Zachary H Hopkins; Ryan P Carlisle; Zachary E Frost; Julia A Curtis; Laura K Ferris; Aaron M Secrest
Journal:  J Clin Aesthet Dermatol       Date:  2021-12

3.  Atrophic Dermatofibroma: A Unique Dermatofibroma Variant.

Authors:  Nikolas Gutierrez; Antoanella Calame; Christof Erickson; Philip R Cohen
Journal:  Cureus       Date:  2021-04-19

4.  Red Nodule in a Post-surgical Scar: A Quiz.

Authors:  Piotr K Krajewski; Iwona Chlebicka; Kinga Tyczyńska; Jacek C Szepietowski
Journal:  Acta Derm Venereol       Date:  2020-06-15       Impact factor: 3.875

5.  Cytotoxic Effect of Vanicosides A and B from Reynoutria sachalinensis Against Melanotic and Amelanotic Melanoma Cell Lines and in silico Evaluation for Inhibition of BRAFV600E and MEK1.

Authors:  Izabela Nawrot-Hadzik; Anna Choromańska; Renata Abel; Robert Preissner; Jolanta Saczko; Adam Matkowski; Jakub Hadzik
Journal:  Int J Mol Sci       Date:  2020-06-29       Impact factor: 5.923

6.  Amelanotic Malignant Melanoma with a BRAF V600E Mutation Mimicking Primary Lung Cancer.

Authors:  Reiko Matsuzawa; Masahiro Morise; Ichidai Tanaka; Shunsaku Hayai; Yutaro Tamiya; Junji Koyama; Tetsunari Hase; Keiko Wakahara; Deoksu Kim; Yoshie Shimoyama; Naozumi Hashimoto
Journal:  Intern Med       Date:  2021-08-24       Impact factor: 1.271

7.  Amelanotic nodular melanoma misdiagnosed as a benign skin lesion: A rare case report from Syria.

Authors:  Mohammed Moutaz Alshaghel; Lana Almahairi; Roua Arian; Mohamad Shehab Alyousfi; Weaam Majanni; Rama Alyousfi; Aladdin Etr
Journal:  Ann Med Surg (Lond)       Date:  2022-01-26

Review 8.  Oral Amelanotic Melanoma: A Systematic Review of Case Reports and Case Series.

Authors:  Shivani P Bansal; Sonal Sunil Dhanawade; Ankita Satish Arvandekar; Vini Mehta; Rajiv S Desai
Journal:  Head Neck Pathol       Date:  2021-07-26

9.  Primary acral amelanotic melanoma: A rare case report.

Authors:  Jiaojiao Zhang; Huizhi Yang; Jiaxi Lin; Fang Zhang; Jianqiang Shi; Rongyi Chen
Journal:  Mol Clin Oncol       Date:  2020-09-03

10.  The Anticancer Potential of Doxycycline and Minocycline-A Comparative Study on Amelanotic Melanoma Cell Lines.

Authors:  Jakub Rok; Zuzanna Rzepka; Justyna Kowalska; Klaudia Banach; Artur Beberok; Dorota Wrześniok
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.